Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 103

1.

Pasireotide is more effective than octreotide in reducing hepatorenal cystogenesis in rodents with polycystic kidney and liver diseases.

Masyuk TV, Radtke BN, Stroope AJ, Banales JM, Gradilone SA, Huang B, Masyuk AI, Hogan MC, Torres VE, Larusso NF.

Hepatology. 2013 Jul;58(1):409-21. doi: 10.1002/hep.26140. Epub 2013 Mar 6.

PMID:
23172758
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Octreotide inhibits hepatic cystogenesis in a rodent model of polycystic liver disease by reducing cholangiocyte adenosine 3',5'-cyclic monophosphate.

Masyuk TV, Masyuk AI, Torres VE, Harris PC, Larusso NF.

Gastroenterology. 2007 Mar;132(3):1104-16. Epub 2006 Dec 20.

PMID:
17383431
[PubMed - indexed for MEDLINE]
3.

Inhibition of Cdc25A suppresses hepato-renal cystogenesis in rodent models of polycystic kidney and liver disease.

Masyuk TV, Radtke BN, Stroope AJ, Banales JM, Masyuk AI, Gradilone SA, Gajdos GB, Chandok N, Bakeberg JL, Ward CJ, Ritman EL, Kiyokawa H, LaRusso NF.

Gastroenterology. 2012 Mar;142(3):622-633.e4. doi: 10.1053/j.gastro.2011.11.036. Epub 2011 Dec 7.

PMID:
22155366
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

Differential antiinflammatory and antinociceptive effects of the somatostatin analogs octreotide and pasireotide in a mouse model of immune-mediated arthritis.

Imhof AK, Glück L, Gajda M, Lupp A, Bräuer R, Schaible HG, Schulz S.

Arthritis Rheum. 2011 Aug;63(8):2352-62. doi: 10.1002/art.30410.

PMID:
21506098
[PubMed - indexed for MEDLINE]
Free Article
5.

The cAMP effectors Epac and protein kinase a (PKA) are involved in the hepatic cystogenesis of an animal model of autosomal recessive polycystic kidney disease (ARPKD).

Banales JM, Masyuk TV, Gradilone SA, Masyuk AI, Medina JF, LaRusso NF.

Hepatology. 2009 Jan;49(1):160-74. doi: 10.1002/hep.22636.

PMID:
19065671
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

The zebrafish as a model to study polycystic liver disease.

Tietz Bogert PS, Huang BQ, Gradilone SA, Masyuk TV, Moulder GL, Ekker SC, Larusso NF.

Zebrafish. 2013 Jun;10(2):211-7. doi: 10.1089/zeb.2012.0825. Epub 2013 May 13.

PMID:
23668934
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

Effect of calcium-sensing receptor activation in models of autosomal recessive or dominant polycystic kidney disease.

Wang X, Harris PC, Somlo S, Batlle D, Torres VE.

Nephrol Dial Transplant. 2009 Feb;24(2):526-34. doi: 10.1093/ndt/gfn527. Epub 2008 Sep 30.

PMID:
18826972
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

Young women with polycystic liver disease respond best to somatostatin analogues: a pooled analysis of individual patient data.

Gevers TJ, Inthout J, Caroli A, Ruggenenti P, Hogan MC, Torres VE, Nevens F, Drenth JP.

Gastroenterology. 2013 Aug;145(2):357-65.e1-2. doi: 10.1053/j.gastro.2013.04.055. Epub 2013 May 7.

PMID:
23665274
[PubMed - indexed for MEDLINE]
9.

VEGF receptor inhibition blocks liver cyst growth in pkd2(WS25/-) mice.

Amura CR, Brodsky KS, Groff R, Gattone VH, Voelkel NF, Doctor RB.

Am J Physiol Cell Physiol. 2007 Jul;293(1):C419-28. Epub 2007 May 2.

PMID:
17475663
[PubMed - indexed for MEDLINE]
Free Article
10.

Randomized clinical trial of long-acting somatostatin for autosomal dominant polycystic kidney and liver disease.

Hogan MC, Masyuk TV, Page LJ, Kubly VJ, Bergstralh EJ, Li X, Kim B, King BF, Glockner J, Holmes DR 3rd, Rossetti S, Harris PC, LaRusso NF, Torres VE.

J Am Soc Nephrol. 2010 Jun;21(6):1052-61. doi: 10.1681/ASN.2009121291. Epub 2010 Apr 29.

PMID:
20431041
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

Insignificant effect of secretin in rodent models of polycystic kidney and liver disease.

Wang X, Ye H, Ward CJ, Chu JY, Masyuk TV, Larusso NF, Harris PC, Chow BK, Torres VE.

Am J Physiol Renal Physiol. 2012 Oct;303(7):F1089-98. doi: 10.1152/ajprenal.00242.2012. Epub 2012 Jul 18.

PMID:
22811488
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

Activation of Trpv4 reduces the hyperproliferative phenotype of cystic cholangiocytes from an animal model of ARPKD.

Gradilone SA, Masyuk TV, Huang BQ, Banales JM, Lehmann GL, Radtke BN, Stroope A, Masyuk AI, Splinter PL, LaRusso NF.

Gastroenterology. 2010 Jul;139(1):304-14.e2. doi: 10.1053/j.gastro.2010.04.010. Epub 2010 Apr 14.

PMID:
20399209
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

Cyclic AMP promotes growth and secretion in human polycystic kidney epithelial cells.

Belibi FA, Reif G, Wallace DP, Yamaguchi T, Olsen L, Li H, Helmkamp GM Jr, Grantham JJ.

Kidney Int. 2004 Sep;66(3):964-73.

PMID:
15327388
[PubMed - indexed for MEDLINE]
14.

Somatostatin analogs for diagnosis and treatment of cancer.

Weckbecker G, Raulf F, Stolz B, Bruns C.

Pharmacol Ther. 1993 Nov;60(2):245-64. Review.

PMID:
7912834
[PubMed - indexed for MEDLINE]
15.

Reducing polycystic liver volume in ADPKD: effects of somatostatin analogue octreotide.

Caroli A, Antiga L, Cafaro M, Fasolini G, Remuzzi A, Remuzzi G, Ruggenenti P.

Clin J Am Soc Nephrol. 2010 May;5(5):783-9. doi: 10.2215/CJN.05380709. Epub 2010 Feb 25.

PMID:
20185596
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

Somatostatin receptors in pituitary and development of somatostatin receptor subtype-selective analogs.

Shimon I.

Endocrine. 2003 Apr;20(3):265-9. Review.

PMID:
12721506
[PubMed - indexed for MEDLINE]
17.

Aberrant expression of laminin-332 promotes cell proliferation and cyst growth in ARPKD.

Vijayakumar S, Dang S, Marinkovich MP, Lazarova Z, Yoder B, Torres VE, Wallace DP.

Am J Physiol Renal Physiol. 2014 Mar 15;306(6):F640-54. doi: 10.1152/ajprenal.00104.2013. Epub 2013 Dec 26.

PMID:
24370592
[PubMed - indexed for MEDLINE]
18.

Effects of angiogenic factor overexpression by human and rodent cholangiocytes in polycystic liver diseases.

Fabris L, Cadamuro M, Fiorotto R, Roskams T, Spirlì C, Melero S, Sonzogni A, Joplin RE, Okolicsanyi L, Strazzabosco M.

Hepatology. 2006 May;43(5):1001-12.

PMID:
16628643
[PubMed - indexed for MEDLINE]
19.

BIM-23A760, a chimeric molecule directed towards somatostatin and dopamine receptors, vs universal somatostatin receptors ligands in GH-secreting pituitary adenomas partial responders to octreotide.

Jaquet P, Gunz G, Saveanu A, Barlier A, Dufour H, Taylor J, Dong J, Kim S, Moreau JP, Culler MD.

J Endocrinol Invest. 2005;28(11 Suppl International):21-7.

PMID:
16625841
[PubMed - indexed for MEDLINE]
20.

Lanreotide reduces the volume of polycystic liver: a randomized, double-blind, placebo-controlled trial.

van Keimpema L, Nevens F, Vanslembrouck R, van Oijen MG, Hoffmann AL, Dekker HM, de Man RA, Drenth JP.

Gastroenterology. 2009 Nov;137(5):1661-8.e1-2. doi: 10.1053/j.gastro.2009.07.052. Epub 2009 Jul 29.

PMID:
19646443
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk